WASHINGTON - A congressional investigation into ImClone Systems Inc.'s handling of the cancer drug Erbitux eventually could end in a more transparent FDA. (BioWorld Today)

WASHINGTON - A congressional investigation into ImClone Systems Inc.'s handling of the cancer drug Erbitux eventually could end in a more transparent FDA. (BioWorld Today)